share_log

BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

Brief-Seelos Treeutics宣佈收購IX Biophma的舌下氯胺酮專有晶片遞送平臺的獨家許可證
reuters ·  2021/11/24 21:24

Nov 24 (Reuters) - Seelos Therapeutics Inc SEEL.O :

路透11月24日電-Seelos治療公司SEEL.O:

* SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE LICENSE OF IX BIOPHARMA'S PROPRIETARY WAFER-BASED DELIVERY PLATFORM FOR SUBLINGUAL KETAMINE

*SEELOS治療公司宣佈收購IX BioPharma公司基於晶片的舌下氯胺酮專有遞送平臺的獨家許可證

* SEELOS THERAPEUTICS INC - NEW SLS-003 PROGRAM EXTENDS SEELOS' KETAMINE FRANCHISE INTO ADDITIONAL INDICATIONS INCLUDING CHRONIC NEUROPATHIC PAIN

*SEELOS治療公司-新的SLS-003計劃將SEELOS的氯胺酮專營權擴大到其他適應症,包括慢性神經性疼痛

* SEELOS THERAPEUTICS INC - SEELOS PLANS TO EVALUATE SUBLINGUAL KETAMINE, NOW NAMED SLS-003, IN PAIN INDICATIONS

*SEELOS治療公司-SEELOS計劃評估舌下氯胺酮,現在命名為SLS-003,用於疼痛適應症

* SEELOS THERAPEUTICS INC - PURSUANT TO LICENSE AGREEMENT, SEELOS WILL PAY IX BIOPHARMA A ONE-TIME, UPFRONT FEE OF $9 MILLION

*SEELOS治療公司-根據許可協議,SEELOS將向IX BioPharma A一次性支付900萬美元的預付費用

Source text for Eikon: ID:nPn7sB5Xna Further company coverage: SEEL.O

Eikon的源文本:ID:nPn7sB5Xna進一步的公司報道:SEEL.O

((Reuters.Briefs@thomsonreuters.com;;))

(Reurs.Briefs@thomsonreurs.com;;)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論